These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 33714790)

  • 1. Pharmacodynamics of once- versus twice-daily dosing of nebulized amikacin in an in vitro Hollow-Fiber Infection Model against 3 clinical isolates of Pseudomonas aeruginosa.
    Heffernan AJ; Sime FB; Naicker S; Andrews K; Ellwood D; Guerra-Valero Y; Wallis S; Lipman J; Grimwood K; Roberts JA
    Diagn Microbiol Infect Dis; 2021 Jun; 100(2):115329. PubMed ID: 33714790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy.
    Sime FB; Johnson A; Whalley S; Santoyo-Castelazo A; Montgomery AB; Walters KA; Lipman J; Hope WW; Roberts JA
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against Pseudomonas aeruginosa in a Dynamic
    Heffernan AJ; Sime FB; Sarovich DS; Neely M; Guerra-Valero Y; Naicker S; Cottrell K; Harris P; Andrews KT; Ellwood D; Wallis SC; Lipman J; Grimwood K; Roberts JA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32660986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model.
    Avent ML; McCarthy KL; Sime FB; Naicker S; Heffernan AJ; Wallis SC; Paterson DL; Roberts JA
    Microbiol Spectr; 2022 Jun; 10(3):e0052522. PubMed ID: 35442072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nebulized Amikacin and Fosfomycin for Severe Pseudomonas aeruginosa Pneumonia: An Experimental Study.
    Li Bassi G; Motos A; Fernandez-Barat L; Aguilera Xiol E; Chiurazzi C; Senussi T; Saco MA; Fuster C; Carbonara M; Bobi J; Amaro R; De Rosa F; Comaru T; Yang H; Ranzani OT; Marti JD; Rinaudo M; Comino Trinidad O; Rigol M; Bringué J; Ramirez J; Nicolau DP; Pelosi P; Antonelli M; Blasi F; Artigas A; Montgomery AB; Torres A
    Crit Care Med; 2019 Jun; 47(6):e470-e477. PubMed ID: 30882478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model.
    McGrath BJ; Lamp KC; Rybak MJ
    Antimicrob Agents Chemother; 1993 Sep; 37(9):1931-7. PubMed ID: 8239608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single daily dosing of amikacin in an in-vitro model.
    Dudley MN; Zinner SH
    J Antimicrob Chemother; 1991 May; 27 Suppl C():15-9. PubMed ID: 1906862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem.
    So W; Crandon JL; Hamada Y; Nicolau DP
    J Antimicrob Chemother; 2016 Feb; 71(2):428-37. PubMed ID: 26559690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptive resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis model.
    Xiong YQ; Caillon J; Kergueris MF; Drugeon H; Baron D; Potel G; Bayer AS
    Antimicrob Agents Chemother; 1997 Apr; 41(4):823-6. PubMed ID: 9087497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the Epithelial Lining Fluid Milieu on Amikacin Pharmacodynamics Against Pseudomonas aeruginosa.
    Heffernan AJ; Sime FB; Lim SMS; Naicker S; Andrews KT; Ellwood D; Lipman J; Grimwood K; Roberts JA
    Drugs R D; 2021 Jun; 21(2):203-215. PubMed ID: 33797739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development.
    Tam VH; Ledesma KR; Vo G; Kabbara S; Lim TP; Nikolaou M
    Antimicrob Agents Chemother; 2008 Nov; 52(11):3987-93. PubMed ID: 18725438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics of inhaled amikacin (BAY 41-6551) studied in an in vitro pharmacokinetic model of infection.
    Bowker KE; Noel AR; Tomaselli S; Attwood M; MacGowan AP
    J Antimicrob Chemother; 2018 May; 73(5):1305-1313. PubMed ID: 29562340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bactericidal kinetics of an in vitro infection model of once-daily ceftriaxone plus amikacin against gram-positive and gram-negative bacteria.
    Scaglione F; Dugnani S; Demartini G; Arcidiacono MM; Cocuzza CE; Fraschini F
    Chemotherapy; 1995; 41(4):239-46. PubMed ID: 7555203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibacterial Activity of Human Simulated Epithelial Lining Fluid Concentrations of Ceftazidime-Avibactam Alone or in Combination with Amikacin Inhale (BAY41-6551) against Carbapenem-Resistant Pseudomonas aeruginosa and Klebsiella pneumoniae.
    Almarzoky Abuhussain SS; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29914950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection of Amikacin Hyper-Resistant Pseudomonas aeruginosa After Stepwise Exposure to High Amikacin Concentrations.
    Amábile-Cuevas CF
    Microb Drug Resist; 2017 Jan; 23(1):32-36. PubMed ID: 27183474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model.
    Robaux MA; Dube L; Caillon J; Bugnon D; Kergueris MF; Navas D; Le Conte P; Baron D; Potel G
    J Antimicrob Chemother; 2001 May; 47(5):617-22. PubMed ID: 11328773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of once- and thrice-daily dosing of aminoglycosides in in-vitro models of infection.
    Blaser J
    J Antimicrob Chemother; 1991 May; 27 Suppl C():21-8. PubMed ID: 1906863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibacterial activity of human simulated epithelial lining fluid concentrations of amikacin inhale alone and in combination with meropenem against Acinetobacter baumannii.
    Ghazi IM; Grupper M; Nicolau DP
    Infect Dis (Lond); 2017; 49(11-12):831-839. PubMed ID: 28758820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
    Bergen PJ; Li J; Nation RL; Turnidge JD; Coulthard K; Milne RW
    J Antimicrob Chemother; 2008 Mar; 61(3):636-42. PubMed ID: 18227094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model.
    Tessier PR; Nicolau DP; Onyeji CO; Nightingale CH
    Chemotherapy; 1999; 45(4):284-95. PubMed ID: 10394012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.